Amyris Inc (NASDAQ:AMRS) Director Patrick Y. Yang acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The stock was acquired at an average price of $7.71 per share, with a total value of $77,100.00. Following the acquisition, the director now owns 36,932 shares in the company, valued at $284,745.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ AMRS traded down $0.06 during trading hours on Monday, reaching $7.67. The company’s stock had a trading volume of 666,100 shares, compared to its average volume of 638,915. The firm has a market cap of $389.11 million, a PE ratio of -2.53 and a beta of 0.11. Amyris Inc has a 52 week low of $1.86 and a 52 week high of $8.08. The company has a debt-to-equity ratio of -0.35, a current ratio of 0.67 and a quick ratio of 0.62.

Amyris (NASDAQ:AMRS) last released its earnings results on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The business had revenue of $24.81 million for the quarter, compared to analyst estimates of $37.52 million. The business’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.32) earnings per share. research analysts anticipate that Amyris Inc will post -1.41 earnings per share for the current fiscal year.

AMRS has been the subject of a number of research reports. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the company a “buy” rating in a report on Friday, May 25th. BidaskClub lowered shares of Amyris from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 17th. Zacks Investment Research lowered shares of Amyris from a “hold” rating to a “strong sell” rating in a report on Monday, June 4th. ValuEngine lowered shares of Amyris from a “buy” rating to a “hold” rating in a report on Friday, June 1st. Finally, B. Riley set a $10.00 price objective on shares of Amyris and gave the company a “buy” rating in a report on Tuesday, May 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $9.13.

A number of large investors have recently added to or reduced their stakes in AMRS. BlackRock Inc. increased its position in Amyris by 3,109.9% during the 2nd quarter. BlackRock Inc. now owns 1,714,555 shares of the biotechnology company’s stock valued at $10,955,000 after purchasing an additional 1,661,141 shares during the period. Millennium Management LLC acquired a new stake in Amyris during the 1st quarter valued at approximately $1,643,000. Crown Advisors Management Inc. acquired a new stake in Amyris during the 1st quarter valued at approximately $669,000. JPMorgan Chase & Co. acquired a new stake in Amyris during the 1st quarter valued at approximately $655,000. Finally, Engineers Gate Manager LP acquired a new stake in Amyris during the 2nd quarter valued at approximately $413,000. 24.01% of the stock is owned by institutional investors and hedge funds.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Recommended Story: Average Daily Trade Volume – What It Means In Stock Trading

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.